TcrossGlobal

Clinical Outcomes at 30 Days Post TAVR with the Self-Expanding Valve Navitor: The PORTICO NG Trial

The PORTICO NG trial showed a low incidence of adverse events and perivalvular regurgitation at 30 days after TAVR with the self-expanding Navitor device in patients with symptomatic severe aortic stenosis who were at high/very high surgical risk, as reported by Dr. Michael J. Reardon and colleagues of Houston Methodist DeBakey Heart and Vascular Center, Houston, USA, in the March 27 issue of JACC: Cardiovascular Interventions.

The PORTICO NG study evaluated the safety and benefit of TAVR with Navitor in 260 patients with symp...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.